Jpmorgan Chase & CO Abb Vie Inc. Transaction History

Jpmorgan Chase & CO

$1.27 Trillion
Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Abb Vie Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 54,754,470 shares of ABBV stock, worth $10.5 Billion. This represents 0.9% of its overall portfolio holdings.

Number of Shares

54,754,470

Previous 51,762,491 5.78%

Holding current value

$10.5 Billion

Previous $9.2 Billion 24.72%

% of portfolio

0.9%

Previous 0.75%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	BUY	$169.2 - $216.66 $506 Million - $648 Million	2,991,979 Added 5.78%	54,754,470 $11.5 Billion
Q4 2024 Feb 12, 2025	SELL	$164.99 - $203.87 $90.7 Million - $112 Million	-549,610 Reduced 1.05%	51,762,491 $9.2 Billion
Q3 2024 Dec 26, 2024	SELL	$163.84 - $199.33 $204 Million - $248 Million	-1,245,814 Reduced 2.33%	52,312,101 $10.3 Billion
Q3 2024 Nov 08, 2024	SELL	$163.84 - $199.33 $237 Million - $288 Million	-1,445,814 Reduced 2.7%	52,112,101 $10.3 Billion
Q2 2024 Dec 26, 2024	BUY	$154.79 - $180.76 $224 Million - $261 Million	1,445,814 Added 2.77%	53,557,915 $9.19 Billion
Q2 2024 Aug 12, 2024	BUY	$154.79 - $180.76 $356 Million - $416 Million	2,299,912 Added 4.49%	53,557,915 $9.19 Billion
Q1 2024 Dec 26, 2024	SELL	$159.82 - $182.1 $107 Million - $121 Million	-667,071 Reduced 1.28%	51,445,030 $9.37 Billion
Q1 2024 May 10, 2024	SELL	$159.82 - $182.1 $89.5 Million - $102 Million	-560,308 Reduced 1.08%	51,258,003 $9.33 Billion
Q4 2023 Dec 26, 2024	SELL	$137.6 - $154.97 $12.3 Million - $13.8 Million	-89,155 Reduced 0.17%	52,022,946 $8.06 Billion
Q4 2023 Feb 12, 2024	SELL	$137.6 - $154.97 $470 Million - $529 Million	-3,412,497 Reduced 6.18%	51,818,311 $8.03 Billion
Q3 2023 Nov 14, 2023	SELL	$133.59 - $154.65 $206 Million - $238 Million	-1,541,772 Reduced 2.72%	55,230,808 $8.23 Billion
Q2 2023 Aug 11, 2023	SELL	$132.51 - $164.9 $149 Million - $186 Million	-1,125,984 Reduced 1.94%	56,772,580 $7.65 Billion
Q1 2023 May 18, 2023	BUY	$144.61 - $166.54 $120 Million - $139 Million	832,342 Added 1.46%	57,898,564 $9.23 Billion
Q1 2023 May 11, 2023	SELL	$144.61 - $166.54 $556 Million - $640 Million	-3,843,992 Reduced 6.31%	57,066,222 $9.09 Billion
Q4 2022 Feb 13, 2023	BUY	$138.31 - $165.87 $336 Million - $403 Million	2,431,205 Added 4.16%	60,910,214 $9.84 Billion
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $318 Million - $365 Million	2,368,374 Added 4.22%	58,479,009 $7.85 Billion
Q2 2022 Aug 11, 2022	BUY	$137.62 - $174.96 $278 Million - $353 Million	2,016,437 Added 3.73%	56,110,635 $8.59 Billion
Q1 2022 May 11, 2022	BUY	$131.98 - $163.75 $1.45 Billion - $1.8 Billion	10,989,210 Added 25.49%	54,094,198 $8.77 Billion
Q4 2021 Feb 10, 2022	SELL	$107.43 - $135.93 $84.7 Million - $107 Million	-788,370 Reduced 1.8%	43,104,988 $5.84 Billion
Q3 2021 Nov 12, 2021	BUY	$106.4 - $120.78 $4.67 Billion - $5.3 Billion	43,893,358 New	43,893,358 $4.73 Billion

Others Institutions Holding ABBV

# of Institutions

4,262

Shares Held

1.27B

Call Options Held

17M

Put Options Held

15.5M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $338B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Abb Vie Inc. Transaction History